Markets

Kazia Therapeutics Doses First Participant In Its Arm A Of PNOC035 Platform To Evaluate Paxalisib In Combination With Gemcitabine Toi Treat Atypical Teratoid/Rhabdoid Tumor

Sep 9, 2026 · 07:32 AM ET· updated 2h ago

Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity

Why It Matters

Kazia started testing a new cancer medicine combined with an existing drug on patients for the first time. This is an early step that shows the company is moving its research forward, though it will take a long time to know if it actually works.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

KZIA12.48

+0.47 (+3.91%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.